These antiangiogenic actions not only compromise tumor nutrient provision but also remodel the immune microenvironment through CD8+ T cell proportion elevation, regulatory T cell population reduction, and suppression of immunosuppressive mediators including TGF-β and IL-10, collectively optimizing ICIs efficacy [45]. The gene discussed is CD8A; the disease is neoplasm.